DE68928251T2 - Cs-Peptide von P. Falciparum als allgemeines t-Zellen-Epitop - Google Patents
Cs-Peptide von P. Falciparum als allgemeines t-Zellen-EpitopInfo
- Publication number
- DE68928251T2 DE68928251T2 DE68928251T DE68928251T DE68928251T2 DE 68928251 T2 DE68928251 T2 DE 68928251T2 DE 68928251 T DE68928251 T DE 68928251T DE 68928251 T DE68928251 T DE 68928251T DE 68928251 T2 DE68928251 T2 DE 68928251T2
- Authority
- DE
- Germany
- Prior art keywords
- falciparum
- peptide
- cell epitope
- mhc
- immunogenic compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
- 241000223960 Plasmodium falciparum Species 0.000 title abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 abstract 3
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 abstract 3
- 102000054766 genetic haplotypes Human genes 0.000 abstract 2
- 230000002163 immunogen Effects 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 241000282412 Homo Species 0.000 abstract 1
- 102000043131 MHC class II family Human genes 0.000 abstract 1
- 108091054438 MHC class II family Proteins 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000001717 pathogenic effect Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
- C07K14/445—Plasmodium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F02—COMBUSTION ENGINES; HOT-GAS OR COMBUSTION-PRODUCT ENGINE PLANTS
- F02B—INTERNAL-COMBUSTION PISTON ENGINES; COMBUSTION ENGINES IN GENERAL
- F02B75/00—Other engines
- F02B75/02—Engines characterised by their cycles, e.g. six-stroke
- F02B2075/022—Engines characterised by their cycles, e.g. six-stroke having less than six strokes per cycle
- F02B2075/027—Engines characterised by their cycles, e.g. six-stroke having less than six strokes per cycle four
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/806—Antigenic peptides or proteins
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB888812214A GB8812214D0 (en) | 1988-05-24 | 1988-05-24 | Use of peptide from circumsporozoite protein of p falciparum as universally recognized t-cell epitope |
Publications (2)
Publication Number | Publication Date |
---|---|
DE68928251D1 DE68928251D1 (de) | 1997-09-18 |
DE68928251T2 true DE68928251T2 (de) | 1998-03-12 |
Family
ID=10637401
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE68928251T Expired - Fee Related DE68928251T2 (de) | 1988-05-24 | 1989-05-12 | Cs-Peptide von P. Falciparum als allgemeines t-Zellen-Epitop |
Country Status (11)
Country | Link |
---|---|
US (1) | US5114713A (de) |
EP (1) | EP0343460B1 (de) |
JP (1) | JP2761402B2 (de) |
AT (1) | ATE156841T1 (de) |
AU (1) | AU627459B2 (de) |
CA (1) | CA1340472C (de) |
DE (1) | DE68928251T2 (de) |
DK (1) | DK250589A (de) |
GB (1) | GB8812214D0 (de) |
NZ (1) | NZ229146A (de) |
ZA (1) | ZA893702B (de) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU5649290A (en) * | 1989-04-12 | 1990-11-05 | New York University | Dendritic polymer of multiple antigen peptide system useful as anti-malarial vaccine |
GB8924438D0 (en) * | 1989-10-31 | 1989-12-20 | Hoffmann La Roche | Vaccine composition |
US5547669A (en) * | 1989-11-03 | 1996-08-20 | Immulogic Pharma Corp | Recombinant peptides comprising T cell epitopes of the cat allergen, Fel d I |
IT1241395B (it) * | 1990-04-02 | 1994-01-10 | Eniricerche Spa | Composti immunogenici,il procedimento per la loro sintesi e loro impiego per la preparazione di vaccini antimalaria |
US5500366A (en) * | 1990-09-18 | 1996-03-19 | Biotech Australia Pty. Ltd. | Polynucleotide encoding T-cell epitopes of the protein TraT |
DE4102042A1 (de) * | 1991-01-24 | 1992-07-30 | Bayer Ag | Substituierte aminosaeureamid-derivate deren herstellung und verwendung als fungizide |
DK0614465T3 (da) * | 1991-11-16 | 1999-09-27 | Smithkline Beecham Biolog | Hybridprotein mellem CS fra Plasmodium og HBsAg |
US5928902A (en) * | 1992-02-27 | 1999-07-27 | Smithkline Beecham Biologicals (S.A.) | Hybrid protein between CS from plasmodium and HBsAg |
US6169171B1 (en) | 1992-02-27 | 2001-01-02 | Smithkline Beecham Biologicals (S.A.) | Hybrid protein between CS from plasmodium and HBSAG |
GB9215780D0 (en) * | 1992-07-24 | 1992-09-09 | Univ London Pharmacy | Peptide compounds |
US6261569B1 (en) * | 1992-08-27 | 2001-07-17 | Deakin Research Limited | Retro-, inverso- and retro-inverso synthetic peptide analogues |
US5674977A (en) * | 1993-02-05 | 1997-10-07 | The Ontario Cancer Institute | Branched synthetic peptide conjugate |
US5759551A (en) * | 1993-04-27 | 1998-06-02 | United Biomedical, Inc. | Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines |
JP3795914B2 (ja) * | 1993-04-27 | 2006-07-12 | ユナイテッド・バイオメディカル・インコーポレイテッド | ワクチン用免疫原性lhrhペプチド構築体および合成普遍免疫刺激器 |
WO1995000540A1 (en) * | 1993-06-18 | 1995-01-05 | Robert Webber | Synthetic carrier and immunogen |
DK96493D0 (da) * | 1993-08-26 | 1993-08-26 | Mouritsen Og Elsner Aps | Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden |
AU707083B2 (en) * | 1993-08-26 | 1999-07-01 | Bavarian Nordic Inc. | Inducing antibody response against self-proteins with the aid of foreign T-cell epitopes |
DE69435171D1 (de) | 1993-09-14 | 2009-01-08 | Pharmexa Inc | Pan dr-bindeproteinen zur erhöhung der immunantwort |
US20050049197A1 (en) * | 1993-09-14 | 2005-03-03 | Epimmune Inc. | Induction of immune response against desired determinants |
US6413935B1 (en) * | 1993-09-14 | 2002-07-02 | Epimmune Inc. | Induction of immune response against desired determinants |
GB9422294D0 (en) * | 1994-11-04 | 1994-12-21 | Peptide Therapeutics Ltd | Peptides for anti-allergy treatment |
EP0814843B1 (de) * | 1995-03-31 | 2003-11-26 | Xenova Research Limited | Hapten-träger-konjugate zur anwendung in der drogen-missbrauchs-therapie |
US5840307A (en) * | 1995-03-31 | 1998-11-24 | Immulogic Pharmacuetical Corp. | Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation |
US6410022B1 (en) | 1995-05-01 | 2002-06-25 | Avant Immunotherapeutics, Inc. | Modulation of cholesteryl ester transfer protein (CETP) activity |
CA2223177A1 (en) | 1995-06-06 | 1996-12-12 | The Immune Response Corporation | Method for increasing hdl cholesterol level |
US6846808B1 (en) | 1996-05-01 | 2005-01-25 | Avant Immunotherapeutics, Inc. | Plasmid-based vaccine for treating atherosclerosis |
US6284533B1 (en) | 1996-05-01 | 2001-09-04 | Avant Immunotherapeutics, Inc. | Plasmid-based vaccine for treating atherosclerosis |
EA002545B1 (ru) | 1997-01-21 | 2002-06-27 | Нью Йорк Юниверсити | Универсальные т-клеточные эпитопы, используемые для получения антималярийных вакцин |
DE69704269T2 (de) | 1997-06-11 | 2001-11-22 | Univ London Pharmacy | Dendritische, lysinhaltige Polypeptide zur gezielten Arzneimittelabreichung |
US20030232055A1 (en) * | 2000-07-31 | 2003-12-18 | Ruslan Medzhitov | Innate immune system-directed vaccines |
US20030175287A1 (en) * | 2001-01-03 | 2003-09-18 | Yale University | Innate immune system-directed vaccines |
US7491690B2 (en) * | 2001-11-14 | 2009-02-17 | Northwestern University | Self-assembly and mineralization of peptide-amphiphile nanofibers |
AU2003215280A1 (en) * | 2002-02-15 | 2003-09-09 | Northwestern University | Self-assembly of peptide-amphiphile nanofibers under physiological conditions |
US7554021B2 (en) * | 2002-11-12 | 2009-06-30 | Northwestern University | Composition and method for self-assembly and mineralization of peptide amphiphiles |
AU2004296181A1 (en) * | 2003-12-05 | 2005-06-23 | Northwestern University | Self-assembling peptide amphiphiles and related methods for growth factor delivery |
US20060002941A1 (en) * | 2004-01-23 | 2006-01-05 | Vievax Corp. | Compositions comprising immune response altering agents and methods of use |
NZ555294A (en) * | 2005-01-21 | 2010-07-30 | Univ Northwestern | Methods and amphiphilic compositions for treating damaged nerve cells |
JP2008531733A (ja) * | 2005-03-04 | 2008-08-14 | ノースウエスタン ユニバーシティ | 血管新生性のヘパリン結合エピトープ、ペプチド両親媒性物質、自己集合組成物、および関連する使用法 |
US8076295B2 (en) * | 2007-04-17 | 2011-12-13 | Nanotope, Inc. | Peptide amphiphiles having improved solubility and methods of using same |
BRPI0815395A2 (pt) * | 2007-08-15 | 2015-02-10 | Circassia Ltd | Composição, vetor, produto, formulação farmacêutica, me´todo in vitro para determinar se as células t reconhecem um polipeptídeo, e, método in vitro para determinar se um indivíduo se encontra ou está em risco de uma condição. |
US7642125B2 (en) * | 2007-09-14 | 2010-01-05 | Macronix International Co., Ltd. | Phase change memory cell in via array with self-aligned, self-converged bottom electrode and method for manufacturing |
EP2391383B1 (de) | 2009-02-02 | 2015-12-23 | ChronTech Pharma AB | Codon-optimiertes hepatitis b virus core antigen (hbcag) |
MX2011010780A (es) * | 2009-04-13 | 2011-10-28 | Univ Northwestern | Andamios novedosos basados en peptido para la regeneracion de cartilagos y metodos para su uso. |
US9169304B2 (en) | 2012-05-01 | 2015-10-27 | Pfenex Inc. | Process for purifying recombinant Plasmodium falciparum circumsporozoite protein |
WO2014186409A1 (en) | 2013-05-15 | 2014-11-20 | Chrontech Pharma Ab | Immunogenic compositions for inhibiting hepatitis d virus |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ213303A (en) * | 1984-09-12 | 1988-09-29 | Univ New York | Plasmodium protein, dna sequence and vaccine |
US4826957A (en) * | 1985-07-12 | 1989-05-02 | New York University | Immunogenic recombinant yeast expression product and method for purifying it |
US4886782A (en) * | 1987-02-26 | 1989-12-12 | The United States Of America As Represented By The Department Of Health And Human Services | Malarial immunogen |
US5028425A (en) * | 1988-07-07 | 1991-07-02 | The United States Of America As Represented By The Department Of Health And Human Services | Synthetic vaccine against P. falciparum malaria |
GB8819209D0 (en) * | 1988-08-12 | 1988-09-14 | Research Corp Ltd | Polypeptide & dna encoding same |
-
1988
- 1988-05-24 GB GB888812214A patent/GB8812214D0/en active Pending
-
1989
- 1989-05-11 CA CA000599474A patent/CA1340472C/en not_active Expired - Fee Related
- 1989-05-12 EP EP89108618A patent/EP0343460B1/de not_active Expired - Lifetime
- 1989-05-12 AT AT89108618T patent/ATE156841T1/de not_active IP Right Cessation
- 1989-05-12 DE DE68928251T patent/DE68928251T2/de not_active Expired - Fee Related
- 1989-05-16 NZ NZ229146A patent/NZ229146A/en unknown
- 1989-05-17 ZA ZA893702A patent/ZA893702B/xx unknown
- 1989-05-18 US US07/353,427 patent/US5114713A/en not_active Expired - Fee Related
- 1989-05-22 AU AU35046/89A patent/AU627459B2/en not_active Ceased
- 1989-05-23 DK DK250589A patent/DK250589A/da not_active Application Discontinuation
- 1989-05-24 JP JP1129037A patent/JP2761402B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP2761402B2 (ja) | 1998-06-04 |
EP0343460A3 (de) | 1991-07-31 |
ATE156841T1 (de) | 1997-08-15 |
ZA893702B (en) | 1990-02-28 |
US5114713A (en) | 1992-05-19 |
DK250589A (da) | 1989-11-25 |
DE68928251D1 (de) | 1997-09-18 |
NZ229146A (en) | 1994-09-27 |
AU627459B2 (en) | 1992-08-27 |
JPH0242099A (ja) | 1990-02-13 |
GB8812214D0 (en) | 1988-06-29 |
CA1340472C (en) | 1999-03-30 |
EP0343460B1 (de) | 1997-08-13 |
AU3504689A (en) | 1989-11-30 |
EP0343460A2 (de) | 1989-11-29 |
DK250589D0 (da) | 1989-05-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE68928251T2 (de) | Cs-Peptide von P. Falciparum als allgemeines t-Zellen-Epitop | |
TR200403064T2 (tr) | Tüberkülozun teşhisi ve immünoterapi yolu ile önlenmesine mahsus yöntemler ve bileşikler. | |
DE69529219T2 (de) | Helicobacter proteine und impstoffe | |
BR9305711A (pt) | Vacina à base de urease contra infecção por helicobacter | |
ATE486887T1 (de) | Trägerprotein eines polyepitops | |
ES2074950A1 (es) | Vacuna para la prevencion de la enfermedad reproductiva y respiratoria de la cerda. | |
BR9910973A (pt) | Vacina | |
HUP0101464A2 (hu) | Mutáns rekombináns allergének | |
ES2149776T3 (es) | Modulacion, inducida por un morfogeno, de la respuesta inflamatoria. | |
BR0314373A (pt) | Produto imunogênico estável para a indução de anticorpos contra uma ou várias proteìnas antigênicas em um indivìduo, composições farmacêutica, imunogênica e de vacina e processo de preparação de um produto imunogênico | |
ATE413191T1 (de) | Verwendung of interleukin-1 mutein als impfstoffadjuvans | |
BR0308860A (pt) | Fator viii modificado | |
NO984244D0 (no) | Vaksinesammensetninger og fremgangsmÕter som er nyttige i Õ indusere immunbeskyttelse mot artritogene peptider som er involvert i patogenese av reumatoid artritt | |
EA199900627A1 (ru) | Универсальные т-клеточные эпитопы, используемые для получения антималярийных вакцин | |
ATE157258T1 (de) | Zubereitungen und behandlungen von pneumonia in tieren | |
BR0207015A (pt) | Eritropoientina modificada (epo) com imunogenicidade reduzida | |
BR0207014A (pt) | Antagonista de receptor de interleucina-1 modificada (il-1ra) com imunogenicidade reduzida. | |
SE9604296D0 (sv) | New pharmaceutical formulation of polypeptides | |
FI933210A (fi) | Avirulent vaccin mot rabies | |
PT99923A (pt) | Processo para a preparacao de proteinas hibridas de plasmodium falciparum que contem sequencias dos antigenios da malaria hrpii e serp e de composicoes farmaceuticas que contem estas proteinas | |
BR0207020A (pt) | Fator de estimulação de colÈnia por granulócito (g-csf) modificado com imunogenicidade reduzida | |
SE9702242D0 (sv) | Vaccine compositions V | |
SE9702240D0 (sv) | Vaccine compositions III |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |